Withdrawn study sought better way to time eye injections

NCT ID NCT03435926

Terminated Knowledge-focused Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if how well a person can fix their gaze relates to signs of active disease on eye scans in patients with age-related macular degeneration (ARMD) treated with antiVEGF injections. Researchers planned to follow patients for two years, measuring fixation quality and scan results at each visit. The goal was to improve when to give repeat injections. However, the study was withdrawn before any participants were enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If a link is found, it could help doctors decide when to retreat ARMD patients more precisely, potentially improving treatment timing.
What could go wrong: The study was withdrawn before enrolling anyone, so no results are available. It is unclear if the approach would work in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOROIDAL NEOVASCULARIZATION, VISUAL FIELD, VISUAL ACUITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

choroidal neovascularization wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOROIDAL NEOVASCULARIZATION, VISUAL FIELD, VISUAL ACUITY

Contacts and locations

Locations

University Hospital

Limoges, 87042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.